Latest News and Press Releases

Noom commits to launch a full-featured free tier of its award-winning app by end of summer to support healthy habits for all Americans.

License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with...

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today...

Hengrui and Kailera announced positive topline data from Hengrui’s Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obesity.

With renewed financial strength, WeightWatchers accelerates its transformation with the appointment of key executives including Dr. Kim Boyd as Chief Medical Officer The Company is advancing its...

WeightWatchers and Novo Nordisk expand collaboration to improve medication access through trusted, holistic model of care

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in...

MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss.No...

Patients treated with CX11 (also designated as VCT220) achieved a 9.7% and 9.4% decrease in body weight from baseline after 16 weeks (p≤0.001) in the 160 mg fast and slow titration cohorts,...

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass,...